Posted by Michael Wonder on 03 Jun 2026
Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in oesophageal squamous cell carcinoma, triple negative breast cancer, cervical cancer and gastric or gastro-oesophageal junction adenocarcinoma
2 June 2026 - Approval expands PD-L1 testing onto an automated workflow to support treatment decisions with Keytruda (pembrolizumab).
Agilent Technologies today announced that the US FDA has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the US with oesophageal squamous cell carcinoma, triple-negative breast cancer, cervical cancer, and gastric or gastro-oesophageal junction adenocarcinoma, who may be eligible for treatment with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.
